Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

May 07, 2019 4:03pm EDT

CohBar Reports First Quarter 2019 Financial Results and Business Update

May 07, 2019 9:00am EDT

CohBar Appoints Steven B. Engle as Chief Executive Officer

May 03, 2019 9:00am EDT

CohBar to Resume its Phase 1a/1b Clinical Trial

Apr 26, 2019 3:35pm EDT

CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

Apr 23, 2019 9:00am EDT

CohBar Announces Key Opinion Leader Conference Call and Webcast

Apr 22, 2019 9:00am EDT

CohBar Announces the Appointment of David Greenwood to its Board of Directors

Mar 18, 2019 4:03pm EDT

CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

Mar 04, 2019 9:00am EST

CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019

Feb 11, 2019 9:00am EST

CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

Dec 10, 2018 4:05pm EST

CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer